MediWound Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Public

  • Employees
  • 121

Employees

  • Stock Symbol
  • MDWD

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $13.55
  • (As of Thursday Closing)

MediWound General Information

Description

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • 42 Hayarkon Street
  • Yavne 8122745
  • Israel
+972
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 42 Hayarkon Street
  • Yavne 8122745
  • Israel
+972

MediWound Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MediWound Stock Performance

As of 19-Nov-2026, MediWound’s stock price is $13.55. Its current market cap is $195M with 14.4M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$13.55 $13.61 $11.80 - $19.70 $195M 14.4M 124K -$1.83

MediWound Financials Summary

As of 30-Sep-2026, MediWound has a trailing 12-month revenue of $10M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 151,039 185,865 152,961 54,172
Revenue 10,007 16,959 20,222 18,686
EBITDA (31,852) (23,329) (29,976) (7,142)
Net Income (23,514) (23,879) (30,224) (6,716)
Total Assets 65,495 86,255 73,496 66,459
Total Debt 8,305 8,152 6,513 6,350
Public Fundamental Data provided by Morningstar, Inc. disclaimer

MediWound Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore MediWound‘s full profile, request access.

Request a free trial

MediWound Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel
Pharmaceuticals
Yavne, Israel
121 As of 2025

Mont-Saint-Guibert, Belgium
 

Cambridge, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

MediWound Competitors (2)

One of MediWound’s 2 competitors is NOVADIP, a Venture Capital-Backed company based in Mont-Saint-Guibert, Belgium.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NOVADIP Venture Capital-Backed Mont-Saint-Guibert, Belgium
SolasCure Venture Capital-Backed Cambridge, United Kingdom
You’re viewing 2 of 2 competitors. Get the full list »

MediWound Patents

MediWound Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022230097-A1 Proteolytic enzyme mixture for treating psoriasis Inactive 01-Mar-2021
CA-3210372-A1 Proteolytic enzyme mixture for treating psoriasis Pending 01-Mar-2021
EP-4301401-A1 Proteolytic enzyme mixture for treating psoriasis Inactive 01-Mar-2021
EP-4301401-A4 Proteolytic enzyme mixture for treating psoriasis Inactive 01-Mar-2021
US-20240148842-A1 Proteolytic enzyme mixture for treating psoriasis Inactive 01-Mar-2021 A61K38/4873
To view MediWound’s complete patent history, request access »

MediWound Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

MediWound Acquisitions (1)

MediWound’s most recent deal was a Merger/Acquisition with Polyheal for . The deal was made on 09-Nov-2010.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Polyheal 09-Nov-2010 Merger/Acquisition Surgical Devices
To view MediWound’s complete acquisitions history, request access »

MediWound ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view MediWound’s complete esg history, request access »

MediWound FAQs

  • When was MediWound founded?

    MediWound was founded in 2000.

  • Where is MediWound headquartered?

    MediWound is headquartered in Yavne, Israel.

  • What is the size of MediWound?

    MediWound has 121 total employees.

  • What industry is MediWound in?

    MediWound’s primary industry is Pharmaceuticals.

  • Is MediWound a private or public company?

    MediWound is a Public company.

  • What is MediWound’s stock symbol?

    The ticker symbol for MediWound is MDWD.

  • What is the current stock price of MediWound?

    As of 19-Nov-2026 the stock price of MediWound is $13.55.

  • What is the current market cap of MediWound?

    The current market capitalization of MediWound is $195M.

  • What is MediWound’s current revenue?

    The trailing twelve month revenue for MediWound is $10M.

  • Who are MediWound’s competitors?

    NOVADIP and SolasCure are competitors of MediWound.

  • What is MediWound’s annual earnings per share (EPS)?

    MediWound’s EPS for 12 months was -$1.83.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process